- Kazia presented positive Phase I data for the ongoing study of Cantrixil in ovarian cancer at AACR on 1st April 2019
- The study consisted of 14 patients, whereby 5 out of the 9 evaluable for efficacy achieved stable disease after two cycles and Maximum Tolerated Dose (MTD) of 5mg/kg was determined.
- An expansion cohort is currently underway to seek efficacy signals and initial data from this cohort is expected in 2H 2019
Kazia Therapeutics (ASX: KZA) is excited to share an ASX announcement released this week on its poster presentation to the 2019 American Association of Cancer Research (AACR) Annual Meeting, which summarises new data from Part A of our ongoing phase I study of Cantrixil in ovarian cancer. The poster was presented at the AACR Annual Meeting in Atlanta, Georgia, USA on Monday 1 April 2019.
New Edison Research Report
Edison Research has also released an updated report on Kazia Therapeutics by Dr Dennis Hulme on the AACR presentation – “Cantrixil efficacy data presented at AACR”. Among other things, the report notes that the presentation “reported encouraging evidence from the phase I study that Cantrixil acts to inhibit tumour growth when administered to ovarian cancer patients”. View the report here.
Video interview available on results
Kazia CEO, James Garner also discussed the AACR presentation and the new findings from the Cantrixil phase I study in an interview with Proactive Investors this week. Watch the video below.
Summary of data
Key points from Part A of the Cantrixil study were as follows:
- The patients that were enrolled had advanced ovarian cancer and had failed at least two other lines of therapy prior to the study
- The drug was shown to be generally safe and well tolerated, and was able to reach a dose that would be expected to be in the therapeutic range
- While Part A was a safety study, it also looked at preliminary efficacy signals, with very encouraging outcomes:56% of patients achieved stable disease. This means they had between 20% increase and 30% decrease in size of their tumour
- Within that group, there was one patient who had an even better result – called a partial response. Partial response means that the patient had at least 30% decrease in size of their tumour – this is measured by MRI or CT scan
- The patients were on the study drug for up to six months and four of nine patients did not have disease progression over that period – this is longer than the progression-free survival rate of approximately 3.4 to 4.7 months that has been suggested by other studies in a similar patient group
About Kazia Therapeutics Limited (ASX: KZA)
Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA) is developing cancer treatments for areas which there is a high unmet medical need. Our lead program, GDC-0084, a drug to treat glioblastoma multiforme, the most aggressive brain cancer, has completed phase 1 human trials with strong safety and early efficacy signals. It is currently being prepared for phase 2 human trials.